Increased bone metabolism in a patient undergoing long-term rhG-CSF treatment for idiopathic acquired neutropenia.
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been used mainly for treatment of chemotherapy-induced neutropenia. The reported side effects were of minor importance. We describe a case of long-term treatment with rhG-CSF, in which we observed enhanced bone remodeling.
Woermann
U J
UJ
Central Hematology Laboratory, University of Bern, Inselspital, Switzerland.
Schenk
R
R
Zimmermann
A
A
Tobler
A
A
D000328:Adult; D001842:Bone and Bones / Q000378:metabolism*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor